AdaptNK for Acute Myeloid Leukemia

This trial explores a new treatment called AdaptNK for individuals with acute myeloid leukemia (AML) that has returned or isn't responding to other treatments. AdaptNK employs special immune cells known as natural killer (NK) cells, enhanced by a short course of a protein called interleukin-2 (IL-2), to combat cancer after chemotherapy. The trial will test various doses of AdaptNK to determine the safest and most effective amount. Suitable candidates have AML that hasn't responded to other treatments and aren't currently using certain immune-suppressing medications. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

Yes, you will need to stop taking certain medications. You must be off glucocorticoids and other immunosuppressive medications for at least 28 days before the NK cell infusion. Additionally, there are specific time requirements for stopping other treatments like chemotherapy and targeted agents before joining the trial.

Research has shown that treatments using natural killer (NK) cells, such as AdaptNK, are generally safe for patients with acute myeloid leukemia (AML). In studies, patients receiving NK cell therapies have experienced few serious side effects. The most common issues include mild flu-like symptoms, such as fever or chills, which can be managed.

One study focused on finding the safest dose of AdaptNK and found it safe at certain levels without major side effects. Another study demonstrated that NK cells from donors could help treat relapsed AML and were safe to use.

Researchers are excited about AdaptNK for treating Acute Myeloid Leukemia (AML) because it represents a novel approach using natural killer (NK) cells. Unlike traditional treatments for AML, such as chemotherapy and stem cell transplants, AdaptNK uses a targeted form of immunotherapy that harnesses the body's own immune system to attack cancer cells. This method involves administering a specific number of Total Nucleated Cells (TNC) intravenously, which could potentially improve the precision and reduce the side effects compared to broader, less targeted treatments. By focusing on enhancing the immune response, AdaptNK offers a promising alternative with the potential for greater efficacy and safety in managing AML.

Studies have shown that AdaptNK, a therapy using natural killer (NK) cells, can effectively target acute myeloid leukemia (AML) cells. Research indicates that these NK cells, strengthened by exposure to the common virus human cytomegalovirus (CMV), can fight leukemia cells in both laboratory and patient settings. Specifically, trials using NK cell therapy have demonstrated a significant chance of achieving remission in some patients with AML. Data reveals that for patients with low to intermediate-risk AML who are in remission, there is an 82% chance of staying disease-free for one year. Overall, NK cell therapies show promise as a new way to combat this challenging type of leukemia. Participants in this trial will receive varying doses of the AdaptNK product to evaluate its safety and effectiveness.¹²³⁵⁶